What's Happening?
Andelyn Biosciences, a prominent cell and gene therapy Contract Development and Manufacturing Organization (CDMO) based in Columbus, Ohio, has received full certification under the Initiative for Certification of Manufacturing Capabilities (ICMC) program
from Dark Horse Consulting. This certification recognizes Andelyn's capability to support advanced therapies manufacturing with its quality and production systems. The ICMC program was established to provide an independent evaluation of CDMO capabilities, ensuring compliance with global regulatory standards for commercial manufacturing. This certification underscores Andelyn's commitment to quality, operational readiness, and client service, as it supports innovators in advancing gene therapies from development through clinical and commercial manufacturing.
Why It's Important?
The certification of Andelyn Biosciences is significant as it provides therapeutic developers with confidence in selecting a manufacturing partner. The ICMC certification ensures that Andelyn meets rigorous standards, which is crucial for the success of gene therapy programs. This development is particularly important in the biopharmaceutical industry, where the demand for reliable and compliant manufacturing partners is high. By achieving this certification, Andelyn strengthens its position as a trusted partner in the gene therapy sector, potentially accelerating the development and delivery of innovative therapies to patients.
